Small molecule modulators of copper-induced Abeta aggregation.

Area of Science:

• Medicinal Chemistry
• Neuroscience
• Biochemistry

Background:

• Alzheimer's disease (AD) pathogenesis involves amyloid-beta (Abeta) aggregation, often influenced by metal ions like copper (Cu(II)).
• Developing targeted agents to interact with metal-associated Abeta aggregates is crucial for understanding AD and designing therapies.

Purpose of the Study:

• To design and synthesize novel bifunctional metal chelators with potential as chemical probes and therapeutics for Alzheimer's disease.
• To investigate the metal-binding and Abeta-interacting properties of the synthesized compounds.
• To evaluate their efficacy in modulating Cu(II)-triggered Abeta aggregation.

Main Methods:

• Synthesis and characterization of two bifunctional compounds: 2-[4-(dimethylamino)phenyl]imidazo[1,2-a]pyridine-8-ol (1) and N(1),N(1)-dimethyl-N(4)-(pyridin-2-ylmethylene)benzene-1,4-diamine (2).
• Spectroscopic methods to verify bifunctionality (metal chelation and Abeta interaction).
• Investigation of reactivity with Cu(II)-associated Abeta aggregates and comparison with known chelating agents (CQ, EDTA, phen).

Main Results:

• Compounds 1 and 2 were successfully synthesized and characterized.
• Bifunctional properties for metal chelation and Abeta interaction were confirmed.
• Compounds 1 and 2 demonstrated superior modulation of Cu(II)-triggered Abeta aggregation compared to existing agents.

Conclusions:

• A new class of multifunctional molecules has been developed for Alzheimer's disease research.
• These compounds can serve as chemical tools to study metal-associated events in AD.
• The developed chelators hold potential as therapeutic agents for metal-ion chelation therapy in AD.